MRVI Earnings

MRVI reported its earnings on 2026-02-25, showcasing a revenue of against an estimate of 49.27M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.07 by 0%. The stock experienced a 9.2% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MRVI's earnings announcement on 2026-02-25, the stock price moved by 9.2% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, MRVI's stock price tends to shift by an average of 6.97% in the 10 days leading up to earnings and 6.34% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MRVI's annual revenue to reach 50.60M, while the EPS is projected at -0.05. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MRVI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MRVI's stock price typically moves by 6.97% in the 10 days before its earnings and 6.34% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.05 and revenue of 50.60M.

The earnings call summary presents a positive outlook for Maravai, with strong growth in GMP consumables, cost reductions, and AI-driven efficiency improvements. The Q&A section reinforces this with optimistic management sentiment, broad-based demand, and strong customer traction. Despite an adjusted EBITDA loss, the company's strategic focus on innovation and market expansion suggests potential for future profitability. The lack of negative guidance and anticipated revenue growth further support a positive stock price movement prediction.